アジア太平洋地域の核酸治療薬CDMO市場：2023-2033年

アジア太平洋地域の核酸治療薬CDMOの市場規模は、2022年の9億7,000万米ドルから、予測期間中は13.92%のCAGRで推移し、2033年には40億4,000万米ドルの規模に成長すると予測されています。

遺伝性疾患や慢性疾患の罹患率の増加、核酸生産の改善、規制認可の増加、CDMO製造インフラの拡大などが今後数年の大幅な成長に寄与すると予想されています。核酸治療薬への需要が高まる中、CDMOは世界中の患者がこれらの最先端治療にアクセスできるようになるために不可欠な存在と考えられています。

当レポートでは、アジア太平洋地域の核酸治療薬CDMOの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の詳細分析、競合情勢、主要企業の分析などをまとめています。

市場区分：

セグメンテーション1：化学合成法別

• 固相オリゴヌクレオチド合成
• 液相オリゴヌクレオチド合成

セグメンテーション2：国別

• 中国
• 日本
• インド
• オーストラリア
• その他のアジア太平洋地域

目次

第1章 市場

• 世界市場の展望
  • 市場概要
  • 製品の定義
  • 包含基準と除外基準
  • 主な調査結果
• 業界の展望
  • 主要動向
  • 機会の評価
  • CDMOに好まれる技術
  • CDMOへのアウトソーシングにおいて考慮される要素
• COVID-19が世界の核酸治療薬CDMOに与える影響
• 現在の核酸治療薬CDMOの情勢
• 治療薬での核酸の使用
• 治療薬に合成される核酸のタイプ
  • アンチセンスオリゴヌクレオチド (ASO) とDNAアプタマー
  • RNA干渉 (RNAi) と短鎖干渉RNA (siRNA)
  • マイクロRNA (miRNA)
  • RNAアプタマーとRNAデコイ
  • リボザイム
  • 環状RNA
• 事業力学
  • 影響分析
  • 事業促進要因
  • 事業上の課題
  • 事業機会

第2章 核酸治療薬CDMO市場 (地域別)

• アジア太平洋の核酸治療薬CDMO市場
  • 主な調査結果
  • 市場力学
  • 市場規模・予測

第3章 市場：競合ベンチマーキング・企業プロファイル

• 競合ベンチマーキング
• 企業プロファイル
  • Asymchem Inc.
  • BioCina
  • CMIC HOLDINGS Co., Ltd.
  • Kaneka Corporation
  • Nippon Shkubai Co., Ltd
  • Nitto Group
  • ST Pharm

List of Figures

• Figure 1: Services Offered by CDMOs
• Figure 2: Nucleic Acid Therapeutics CDMO Market, Impact Analysis
• Figure 3: Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Method), % Share, 2022 and 2033
• Figure 4: Nucleic Acid Therapeutics CDMO Market (by Region), $Billion, 2022 and 2033
• Figure 5: Nucleic Acid Therapeutics CDMO Market: Research Methodology
• Figure 6: Primary Research Methodology
• Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 8: Top-Down Approach (Segment-Wise Analysis)
• Figure 9: Significant Number of Collaborations among Market Players in Nucleic Acid Therapeutics CDMO Market, 2019-2023
• Figure 10: Core CDMO Services
• Figure 11: Nucleic Acid Therapeutics CDMO Market Key Trends, Market Shift, 2022-2033
• Figure 12: Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
• Figure 13: Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
• Figure 14: Preferred Techniques by CDMOs for Nucleic Acid Purification
• Figure 15: Factors considered while outsourcing to CDMO.
• Figure 16: Nucleic Acid Therapeutics CDMO Market, Impact Analysis
• Figure 17: Significant Increase in Sale of TEGSEDI and WAYLIVRA Drugs in $Million, 2018-2021
• Figure 18: Significant Number of Nucleic Acid Drugs Approved by FDA or EMA in Global Nucleic Acid Therapeutics CDMO Market, 2018-2020
• Figure 19: Nucleic Acid Therapeutics CDMO Market Share (by Region), 2022-2033
• Figure 20: Incidence of Hematologic Malignancies, Asia, 2020 vs. 2040
• Figure 21: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
• Figure 22: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
• Figure 23: Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country), % Share, 2022 and 2033
• Figure 24: Japan Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
• Figure 25: Japan Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
• Figure 26: China Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
• Figure 27: China Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
• Figure 28: India Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
• Figure 29: India Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
• Figure 30: Australia Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
• Figure 31: Australia Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
• Figure 32: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market, $Billion, 2022-2033
• Figure 33: Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods), $Million, 2022-2033
• Figure 34: Global Nucleic Acid Therapeutics CDMO Market, Number of Key Developments and Strategies, January 2018-February 2023
• Figure 35: Funding Activities, January 2018-February 2023
• Figure 36: New Offerings, January 2018-February 2023
• Figure 37: Mergers and Acquisitions, January 2018-February 2023
• Figure 38: Partnerships and Collaborations, January 2018-February 2023
• Figure 39: Business Expansions, January 2018-February 2023
• Figure 40: Regulatory and Legal Activities, January 2018-February 2023
• Figure 41: Global Nucleic Acid Therapeutics CDMO Market, Company Revenue Share Analysis, $Billion, 2022
• Figure 42: Some of the Active Players in the Nucleic Acid Therapeutics CDMO Market
• Figure 43: Asymchem Inc.: Product Portfolio
• Figure 44: Asymchem Inc.: Overall Financials, $Million, 2021-2022
• Figure 45: Asymchem Inc.: Net Revenue (by Segment), $Million, 2021-2022
• Figure 46: Asymchem Inc.: Net Revenue (by Region), $Million, 2021-2022
• Figure 47: Asymchem Inc.: R&D Expenditure, $Million, 2021-2022
• Figure 48: BioCina: Product Portfolio
• Figure 49: CMIC HOLDINGS Co., Ltd.: Product Portfolio
• Figure 50: CMIC HOLDINGS Co., Ltd.: Overall Financials, $Million, 2020-2022
• Figure 51: CMIC HOLDINGS Co., Ltd.: Segment Revenues, $Million, 2020-2022
• Figure 52: CMIC HOLDINGS Co., Ltd.: Net Revenue (by Region), $Million, 2020-2022
• Figure 53: CMIC HOLDINGS Co., Ltd.: R&D Expenditure, $Million, 2020-2022
• Figure 54: Kaneka Corporation: Product Portfolio
• Figure 55: Kaneka Corporation: Overall Financials, $Million, 2019-2021
• Figure 56: Kaneka Corporation: Net Revenue (by Segment), $Million, 2019-2021
• Figure 57: Kaneka Corporation: Net Revenue (by Region), $Million, 2019-2021
• Figure 58: Kaneka Corporation: R&D Expenditure, $Million, 2019-2021
• Figure 59: Nippon Shokubai Co., Ltd: Product Portfolio
• Figure 60: Nippon Shokubai Co., Ltd: Overall Financials, $Million, 2019-2021
• Figure 61: Nippon Shokubai Co., Ltd: Segment Revenues, $Million, 2019-2021
• Figure 62: Nitto Group: Product Portfolio
• Figure 63: Nitto Group: Overall Financials, $Million, 2019-2021
• Figure 64: Nitto Group: Segment Revenues, $Million, 2019-2021
• Figure 65: Nitto Group: Net Revenue (by region), $Million, 2019-2021
• Figure 66: Nitto Group: R&D Expenditure, $Million, 2019-2021
• Figure 67: ST Pharm: Product Portfolio
• Figure 68: ST Pharm: Overall Financials, $Million, 2019-2021
• Figure 69: ST Pharm: Net Revenue (by Segment), $Million, 2019-2021

List of Tables

• Table 1: Nucleic Acid Therapeutics CDMO Market, Key Developments Analysis, January 2018-February 2023
• Table 2: Key Questions Answered in the Report
• Table 3: Some of the Partnerships and Collaborations in the Global Nucleic Acid Therapeutics CDMO Market
• Table 4: Nucleic Acid Therapeutics CDMO Market, Key Investment
• Table 5: Nucleic Acid Drugs Approved by FDA or EMA, 2018-2021
• Table 6: Advancements in Manufacturing Units of CDMO
• Table 7: Asia-Pacific Nucleic Acid Therapeutics CDMO Market, Impact Analysis

“The Asia-Pacific Nucleic Acid Therapeutics CDMO Market Expected to Reach $4.04 Billion by 2033.”

Introduction to Asia-Pacific (APAC) Nucleic Acid Therapeutics CDMO Market

The APAC Nucleic Acid Therapeutics CDMO Market is expected to grow at a CAGR of 13.92% from $0.97 billion in 2022 to $4.04 billion by 2033 in the forecasted period of 2023-2033. The increasing incidence of hereditary and chronic illnesses, improvements in nucleic acid production, a rise in regulatory approvals, and an expanding CDMO manufacturing infrastructure are all expected to contribute to the significant growth of the APAC nucleic acid therapies CDMO market in the years to come. With the increasing demand for nucleic acid therapeutics, CDMOs will be essential in enabling patients all around the world to access these cutting-edge treatments.

Market Introduction

With the rising incidence of genetic and chronic illnesses, growing regulatory approvals, growing CDMO manufacturing infrastructure, and encouraging government initiatives, the APAC nucleic acid therapeutics CDMO market is expected to grow significantly in the next years. With the increasing demand for nucleic acid therapeutics, CDMOs will be essential in enabling patients all around the world to access these cutting-edge treatments.

Market Segmentation:

Segmentation 1: by Chemical Synthesis Method

• Solid-Phase Oligonucleotide Synthesis
• Liquid-Phase Oligonucleotide Synthesis

Segmentation 2: by Country

• China
• Japan
• India
• Australia
• Rest-of-Asia-Pacific

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific nucleic acid therapeutics CDMO market:

• Increasing Presence of Established Players in the Region
• Funding Support and Investments from the Government
• Low Cost of Manufacturing

The market is expected to face some limitations as well due to the following challenges:

• Lack of Expertise in Developing Nucleic Acid Therapeutics

How can this report add value to an organization?

Product/Innovation Strategy: The nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as product, chemical synthesis method, disease type, technology, and end users. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: Key players in the Asia-Pacific nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.

The Asia-Pacific nucleic acid therapeutics CDMO market has witnessed several investments for the expansion of CDMO manufacturing units by the market players. The expansion is aimed at increasing the manufacturing capacity. To meet the growing demand for their services, CDMOs are expanding their manufacturing units and investing in new technologies. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Table of Contents

1 Market

• 1.1 Global Market Outlook
  • 1.1.1 Market Overview
  • 1.1.2 Product Definition
  • 1.1.3 Inclusion and Exclusion Criteria
  • 1.1.4 Key Findings
• 1.2 Industry Outlook
  • 1.2.1 Key Trends
    • 1.2.1.1 Significant Number of Collaborations among Market Players
    • 1.2.1.2 Increasing Investment for Expansion of Nucleic Acid Therapeutics CDMO Manufacturing Units
    • 1.2.1.3 CDMOs Shifting their Business Strategy in Response to a Changing Environment
  • 1.2.2 Opportunity Assessment
  • 1.2.3 Preferred Techniques By CDMO
    • 1.2.3.1 Preferred Techniques by CDMOs for Nucleic Acid Impurity Analysis
    • 1.2.3.2 Preferred Techniques by CDMOs for Nucleic Acid Structural Analysis
    • 1.2.3.3 Preferred Techniques by CDMOs for Nucleic Acid Purification
  • 1.2.4 Factors Considered While Outsourcing To CDMO.
• 1.3 Impact of COVID-19 on the Global Nucleic Acid Therapeutics CDMO
  • 1.3.1 Pre-COVID-19 Phase
  • 1.3.2 During COVID-19
  • 1.3.3 Post-COVID-19 Phase
    • 1.3.3.1 Impact on Demand and Supply
• 1.4 Current Nucleic Acid Therapeutic CDMOs Landscape
• 1.5 Significant Usage of Nucleic Acid in Therapeutics
• 1.6 Types of Nucleic Acid Synthesized for Therapeutics
  • 1.6.1 Anti-Sense Oligonucleotides (ASOs) and DNA Aptamers
  • 1.6.2 RNA Interference (RNAi) and Short Interfering RNAs (siRNAs)
  • 1.6.3 MicroRNAs (miRNAs)
  • 1.6.4 RNA Aptamers and RNA Decoys
  • 1.6.5 Ribozymes
  • 1.6.6 Circular RNAs
• 1.7 Business Dynamics
  • 1.7.1 Impact Analysis
  • 1.7.2 Business Drivers
    • 1.7.2.1 Growing Demand for Nucleic Acid Therapeutics Application to Treat Chronic and Genetic Diseases
    • 1.7.2.2 Increasing FDA or European Medicines Agency (EMA) Approvals of Nucleic Acid Therapeutics
    • 1.7.2.3 Advancements in Manufacturing Units for Producing Nucleic Acid by CDMOs
  • 1.7.3 Business Restraints
    • 1.7.3.1 Substantial Variations in Nucleic Acid Leading to Complications in Therapeutic Classification
    • 1.7.3.2 Lack of Expertise in Developing Nucleic Acid Therapeutic
  • 1.7.4 Business Opportunities
    • 1.7.4.1 Continued Research and Development Activities for Manufacturing Innovative Nucleic Acid Therapeutics Forcing Pharmaceutical Companies to Expand their Businesses.
    • 1.7.4.2 Pharmaceutical Firms Becoming More Outsourcing-Oriented

2 Nucleic Acid Therapeutics CDMO Market (by Region)

• 2.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
    • 2.1.3.2 Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Country)
      • 2.1.3.2.1 Japan
        • 2.1.3.2.1.1 Japan Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.2 China
        • 2.1.3.2.2.1 China Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.3 India
        • 2.1.3.2.3.1 India Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.4 Australia
        • 2.1.3.2.4.1 Australia Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)
      • 2.1.3.2.5 Rest-of-Asia-Pacific
        • 2.1.3.2.5.1 Rest-of-Asia-Pacific Nucleic Acid Therapeutics CDMO Market (by Chemical Synthesis Methods)

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Competitive Benchmarking
  • 3.1.1 Key Strategies and Developments
    • 3.1.1.1 Funding Activities
    • 3.1.1.2 New Offerings
    • 3.1.1.3 Mergers and Acquisitions
    • 3.1.1.4 Partnerships and Collaborations
    • 3.1.1.5 Business Expansions
    • 3.1.1.6 Regulatory and Legal Activities
  • 3.1.2 Market Share Analysis
  • 3.1.3 Visual Graphics of Key Companies
• 3.2 Company Profile
  • 3.2.1 Asymchem Inc.
    • 3.2.1.1 Company Overview
    • 3.2.1.2 Role of Asymchem Inc. in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.1.3 Financials
    • 3.2.1.4 Recent Developments
    • 3.2.1.5 Analyst Perspective
  • 3.2.2 BioCina
    • 3.2.2.1 Company Overview
    • 3.2.2.2 Role of BioCina in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.2.3 Recent Developments
    • 3.2.2.4 Analyst Perspective
  • 3.2.3 CMIC HOLDINGS Co., Ltd.
    • 3.2.3.1 Company Overview
    • 3.2.3.2 Role of CMIC HOLDINGS Co., Ltd. In the Nucleic Acid Therapeutics CDMO Market
    • 3.2.3.3 Financials
    • 3.2.3.4 Analyst Perspective
  • 3.2.4 Kaneka Corporation
    • 3.2.4.1 Company Overview
    • 3.2.4.2 Role of Kaneka Corporation in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.4.3 Financials
    • 3.2.4.4 Recent Developments
    • 3.2.4.5 Analyst Perspective
  • 3.2.5 Nippon Shkubai Co., Ltd
    • 3.2.5.1 Company Overview
    • 3.2.5.2 Role of Nippon Shokubai Co., Ltd in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.5.3 Financials
    • 3.2.5.4 Analyst Perspective
  • 3.2.6 Nitto Group
    • 3.2.6.1 Company Overview
    • 3.2.6.2 Role of Nitto Group in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.6.3 Financials
    • 3.2.6.4 Recent Developments
    • 3.2.6.5 Analyst Perspective
  • 3.2.7 ST Pharm
    • 3.2.7.1 Company Overview
    • 3.2.7.2 Role of ST Pharm in the Nucleic Acid Therapeutics CDMO Market
    • 3.2.7.3 Financials
    • 3.2.7.4 Recent Developments
    • 3.2.7.5 Analyst Perspective